Effectiveness of COVID-19 vaccines among children 6-11 years against hospitalization during Omicron predominance in Malaysia.

Publication date: Mar 08, 2024

There is currently limited data on the effectiveness of COVID-19 vaccines for children aged 6-11 years in Malaysia. This study aims to determine vaccine effectiveness (VE) against COVID-19-related hospitalization after receipt of one- and two-doses of BNT162b2 mRNA (Comirnaty-Pfizer/BioNTech) vaccine over a duration of almost 1 year in the predominantly Omicron period of BA. 4/BA. 5 and X. B.B sub lineages. This study linked administrative databases between May 2022 and March 2023 to evaluate real-world vaccine effectiveness (VE) for the BNT162b2 mRNA (Comirnaty-Pfizer/BioNTech) vaccine against COVID-19-related hospitalization in the Omicron pre-dominant period with BA. 4/BA. 5 and X. B.B sub lineages. During the Omicron-predominant period, the cumulative hospitalization rate was almost two times higher for unvaccinated children (9. 6 per million population) compared to vaccinated children (6 per million population). The estimated VE against COVID-19 hospitalization for one dose of BNT162b2 was 27% (95% CI - 1%, 47%) and 38% (95% CI 27%, 48%) for two doses. The estimated VE against hospitalization remained stable when stratified by time. VE for the first 90 days was estimated to be 45% (95% CI 33, 55%), followed by 47% (95% CI 34, 56%) between 90 and 180 days, and 36% (95% CI 22, 45%) between 180 and 360 days. Recent infection within 6 months does not appear to modify the impact of vaccination on the risk of hospitalization, subject to the caveat of potential underestimation. In our pediatric population, BNT162b2 provided moderate-non-diminishing protection against COVID-19 hospitalization over almost 1 year of Omicron predominance.

Open Access PDF

Concepts Keywords
Databases COVID-19
Malaysia Hospitalization
March Malaysia
Underestimation Vaccine effectiveness


Type Source Name
disease VO effectiveness
disease MESH COVID-19
disease VO vaccine effectiveness
disease VO Comirnaty
disease VO vaccine
disease VO unvaccinated
disease VO population
disease VO vaccinated
disease VO dose
disease VO time
disease MESH infection
disease VO vaccination
drug DRUGBANK Coenzyme M
disease IDO history
disease IDO virulence
disease VO CoronaVac
disease VO effective
disease MESH reinfection
disease IDO country
drug DRUGBANK (S)-Des-Me-Ampa
disease VO primary vaccination
disease MESH morbidities
disease VO immunization
drug DRUGBANK Isoxaflutole
disease MESH asthma
pathway KEGG Asthma
disease MESH Bell’s palsy
disease IDO quality
disease IDO immune response
disease VO vaccine efficacy
disease MESH dehydration
disease MESH chest pain
disease MESH seizures
disease MESH emergency
disease MESH complications
disease VO regulatory agency
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)